Triethanolamine
Nonproprietary Names
BP: Triethanolamine PhEur: Trolaminum USPNF: Trolamine
Synonyms
TEA; Tealan; triethylolamine; trihydroxytriethylamine; tris (hydroxyethyl)amine.
Chemical Names and CAS Registry Number
2,2',2''-Nitrilotriethanol [102-71-6]
Empirical Formula and Molecular Weight
C6H15NO3 149.19
Structural Formula
Functional Category
Alkalizing agent; emulsifying agent.
Applications in Pharmaceutical Formulation or Technology
Triethanolamine is widely used in topical pharmaceutical formulations primarily in the formation of emulsions.
When mixed in equimolar proportions with a fatty acid, such as stearic acid or oleic acid, triethanolamine forms an anionic soap with a pH of about 8, which may be used as an emulsifying agent to produce fine-grained, stable oil-in-water emulsions. Concentrations that are typically used for emulsi- fication are 2–4% v/v of triethanolamine and 2–5 times that of fatty acids. In the case of mineral oils, 5% v/v of triethanol- amine will be needed, with an appropriate increase in the amount of fatty acid used. Preparations that contain trietha- nolamine soaps tend to darken on storage. However, discolora- tion may be reduced by avoiding exposure to light and contact with metals and metal ions.
Triethanolamine is also used in salt formation for injectable solutions and in topical analgesic preparations. It is also used in sun-screen preparations.(1)
Triethanolamine is used as an intermediate in the manu- facturing of surfactants, textile specialties, waxes, polishes, herbicides, petroleum demulsifiers, toilet goods, cement addi- tives, and cutting oils. Triethanolamine is also claimed to be used for the production of lubricants for the rubber gloves and textile industries. Other general uses are as buffers, solvents, and polymer plasticizers, and as a humectant.
See also Section 18.
�Description
Triethanolamine is a clear, colorless to pale yellow-colored viscous liquid having a slight ammoniacal odor. It is a mixture of bases, mainly 2,2',2''-nitrilotriethanol although it also contains 2,2'-iminobisethanol (diethanolamine) and smaller amounts of 2-aminoethanol (monoethanolamine).
Pharmacopeial Specifications
See Table I.
Table I: Pharmacopeial specifications for triethanolamine.
Test PhEur 2005 USPNF 23
Characters + —
Identification + +
Appearance of solution + —
Related substances + —
Heavy metals 410 ppm —
Water 41.0% 40.5%
Sulfated ash 40.1% 40.05%
Impurities + —
Organic volatile impurities — +
Specific gravity — 1.120–1.128
Refractive index — 1.481–1.486
Assay 99.0–103.0% 99.0–107.4%
Typical Properties
Acidity/alkalinity: pH = 10.5 (0.1 N solution)
Boiling point: 3358C Flash point: 2088C Freezing point: 21.68C
Hygroscopicity: very hygroscopic.
Melting point: 20–218C Moisture content: 0.09% Solubility: see Table II.
Table II: Solubility of triethanolamine.
Solvent Solubility at 208C
Acetone Miscible
Benzene 1 in 24
Carbon tetrachloride Miscible
Ethyl ether 1 in 63
Methanol Miscible
Water Miscible
Surface tension: 48.9 mN/m (48.9 dynes/cm) at 258C
Viscosity (dynamic): 590 mPa s (590 cP) at 308C
Triethanolamine 795
Stability and Storage Conditions
Triethanolamine may turn brown on exposure to air and light. The 85% grade of triethanolamine tends to stratify below 158C; homegeneity can be restored by warming and mixing
before use.
Triethanolamine should be stored in an airtight container protected from light, in a cool, dry place.
See Monoethanolamine for further information.
Incompatibilities
Triethanolamine is a tertiary amine that contains hydroxy groups; it is capable of undergoing reactions typical of tertiary amines and alcohols. Triethanolamine will react with mineral acids to form crystalline salts and esters. With the higher fatty acids, triethanolamine forms salts that are soluble in water and have characteristics of soaps. Triethanolamine will also react with copper to form complex salts. Discoloration and precipitation can take place in the presence of heavy metal salts. Triethanolamine can react with reagents such as thionyl chloride to replace the hydroxy groups with halogens. The products of these reactions are very toxic, resembling other
nitrogen mustards.
Method of Manufacture
Triethanolamine is prepared commercially by the ammonolysis of ethylene oxide. The reaction yields a mixture of mono- ethanolamine, diethanolamine, and triethanolamine, which are separated to obtain the pure products.
Safety
Triethanolamine is used primarily as an emulsifying agent in a variety of topical pharmaceutical preparations. Although generally regarded as a nontoxic material,(2) triethanolamine may cause hypersensitivity or be irritant to the skin when present in formulated products. The lethal human oral dose of triethanolamine is estimated to be 5–15 g/kg body-weight.
Following concern about the possible production of nitrosamines in the stomach, the Swiss authorities have restricted the use of triethanolamine to preparations intended for external use.(3)
LD50 (guinea pig, oral): 5.3 g/kg(4) LD50 (mouse, IP): 1.45 g/kg
LD50 (mouse, oral): 7.4 g/kg LD50 (rat, oral): 8 g/kg
Handling Precautions
Triethanolamine may be irritant to the skin, eyes, and mucous membranes. Inhalation of vapor may be harmful. Protective clothing, gloves, eye protection, and a respirator are recom- mended. Ideally, triethanolamine should be handled in a fume cupboard. On heating, triethanolamine forms highly toxic nitrous fumes. Triethanolamine is combustible.
�
Regulatory Status
Included in the FDA Inactive Ingredients Guide (rectal, topical, and vaginal preparations). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.
Related Substances
Diethanolamine; monoethanolamine.
Comments
Various grades of triethanolamine are available. The standard commercial grade contains 85% triethanolamine. The superior grade contains 98–99% triethanolamine.
One volume part of triethanolamine with 5–7 parts of a mixture of CaO2 and ZnO2 is used as a filling material that enhances the restorative process in periodontal tissues. Triethanolamine is recommended as the preferred stabilizer to be used in latex polymerization because of its weak mutagenic effect in the Ames tests.
The EINECS number for triethanolamine is 203-049-8.
Specific References
Turkoglu M, Yener S. Design and in vivo evaluation of ultrafine inorganic-oxide-containing-sunscreen formulations. Int J Cosmet Sci 1997; 19(4): 193–201.
Maekawa A, Onodera H, Tanigawa H, et al. Lack of carcinogeni- city of triethanolamine in F344 rats. J Toxicol Environ Health 1986; 19(3): 345–357.
Anonymous. Trolamine: concerns regarding potential carcinogeni- city. WHO Drug Inf 1991; 5: 9.
Lewis RJ, ed. Sax’s Dangerous Properties of Industrial Materials, 11th edn. New York: Wiley, 2004: 3568.
General References
Friberg SE, Wohn CS, Lockwood FE. The influence of solvent on nonaqueous lyotropic liquid crystalline phase formed by triethan- olamine oleate. J Pharm Sci 1985; 74(7): 771–773.
Ramsay B, Lawrence CM, Bruce JM, Shuster S. The effect of triethanolamine application on anthralin-induced inflammation and therapeutic effect in psoriasis. J Am Acad Dermatol 1990; 23: 73–76.
Yano H, Noda A, Hukuhara T, Miyazawa K. Generation of maillard- type compounds from triethanolamine alone. J Am Oil Chem Soc 1997; 74(7): 891–893.
Authors
SR Goskonda, JC Lee.
Date of Revision
13 April 2005.
Triethyl Citrate
Nonproprietary Names
BP: Triethyl citrate PhEur: Triethylis citras USPNF: Triethyl citrate
Synonyms
Citric acid, ethyl ester; Citroflex 2; Citrofol AI; E1505;
Hydagen CAT; TEC.
Chemical Name and CAS Registry Number
Hydroxy-1,2,3-propanetricarboxylic acid, triethyl ester [77- 93-0]
Empirical Formula and Molecular Weight
C12H20O7 276.29
Structural Formula
Functional Category
Plasticizer.
Applications in Pharmaceutical Formulation or Technology
Triethyl citrate and the related esters acetyltriethyl citrate, tributyl citrate, and acetyltributyl are used to plasticize polymers in formulated pharmaceutical coatings.(1–5) The coating applications include capsules, tablets, beads, and granules for taste masking, immediate release, sustained- release, and enteric formulations.
Triethyl citrate is also used as a direct food additive for flavoring, for solvency, and as a surface active agent.
Description
Triethyl citrate is a clear, odorless, practically colorless, oily liquid.
Pharmacopeial Specifications
See Table I.
�Table I: Pharmacopeial specifications for triethyl citrate.
Test PhEur 2005 USPNF 23
Identification + +
Characters + —
Appearance + —
Specific gravity — 1.135–1.139
Refractive index 1.440–1.446 1.439–1.441
Acidity + +
Related substances + —
Sulfated ash 40.1% —
Heavy metals 45 ppm 40.001%
Water 40.25% 40.25%
Assay (anhydrous basis) 98.5–101.0% 99.0–100.5%
Typical Properties
Acid value: 0.02
Boiling point: 2888C (decomposes)
Flash point: 1558C
Pour point: —458C
Solubility: soluble 1 in 125 of peanut oil, 1 in 15 of water.
Miscible with ethanol (95%), acetone, and propan-2-ol.
Viscosity (dynamic): 35.2 mPa s (35.2 cP) at 258C
Stability and Storage Conditions
Triethyl citrate should be stored in a closed container in a cool, dry location. When stored in accordance with these conditions, triethyl citrate is a stable product.
Incompatibilities
Triethyl citrate is incompatible with strong alkalis and oxidizing materials.
Method of Manufacture
Triethyl citrate is prepared by the esterification of citric acid and ethanol in the presence of a catalyst.
Safety
Triethyl citrate is used in oral pharmaceutical formulations and as a direct food additive. It is generally regarded as a nontoxic and nonirritant material. However, ingestion of large quantities may be harmful.
LD50 (mouse, IP): 1.75 g/kg(6) LD50 (rat, IP): 4 g/kg
LD50 (rat, oral): 5.9 g/kg LD50 (rat, SC): 6.6 g/kg
Handling Precautions
Observe normal precautions appropriate to the circumstances and quantity of material handled. Triethyl citrate is irritating to the eyes and may irritate the skin. Irritating to the respiratory
Triethyl Citrate 797
system as a mist or at elevated temperatures. Gloves, eye protection, and a respirator are recommended.
Regulatory Status
GRAS listed. Accepted for use as a food additive in Europe. Included in the FDA Inactive Ingredients Guide (oral capsules and tablets). Included in the Canadian List of Acceptable Non- medicinal Ingredients.
Related Substances
Acetyltributyl citrate; acetyltriethyl citrate; tributyl citrate.
Comments
A specification for triethyl citrate is contained in the Food Chemicals Codex (FCC). The EINECS number for triethyl citrate is 201-070-7.
Specific References
Gutierrez-Rocca JC, McGinity JW. Influence of water soluble and insoluble plasticizers on the physical and mechanical properties of acrylic resin copolymers. Int J Pharm 1994; 103: 293–301.
�
Lehmann K. Chemistry and application properties of polymetha- crylate coating systems. In: McGinity JW, ed. Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms. New York: Marcel Dekker, 1989: 153–245.
Steurnagel CR. Latex emulsions for controlled drug delivery. In: McGinity JW, ed. Aqueous Polymeric Coatings for Pharmaceutical Dosage Forms. New York: Marcel Dekker, 1989: 1–61.
Gutierrez-Rocca JC, McGinity JW. Influence of aging on the physical–mechanical properties of acrylic resin films cast from aqueous dispersions and organic solutions. Drug Dev Ind Pharm 1993; 19(3): 315–332.
Liu J, Williams R. Properties of heat-humidity cured cellulose acetate phthalate free films. Eur J Pharm Sci 2002; 17(1–2): 31–41.
Lewis RJ, ed. Sax’s Dangerous Properties of Industrial Materials, 11th edn. New York: Wiley, 2004: 3546.
General References
—
Authors
SW Kennedy.
Date of Revision
13 August 2005.
Vanillin
Nonproprietary Names
BP: Vanillin PhEur: Vanillinum USPNF: Vanillin
Synonyms
4-Hydroxy-m-anisaldehyde; p-hydroxy-m-methoxybenz- aldehyde; 3-methoxy-4-hydroxybenzaldehyde; methylproto- catechuic aldehyde; Rhovanil; vanillic aldehyde.
Chemical Name and CAS Registry Number
4-Hydroxy-3-methoxybenzaldehyde [121-33-5]
Empirical Formula and Molecular Weight
�Vanillin has also been investigated as a photostabilizer in furosemide 1% w/v injection, haloperidol 0.5% w/v injection, and thiothixene 0.2% w/v injection.(5)
Description
White or cream, crystalline needles or powder with character- istic vanilla odor and sweet taste.
Pharmacopeial Specifications
See Table I.
Table I: Pharmacopeial specifications for vanillin.
C H O 152.15
8 8 3
Structural Formula
Functional Category
Flavoring agent.
Applications in Pharmaceutical Formulation or Technology
Vanillin is widely used as a flavor in pharmaceuticals, foods, beverages, and confectionery products, to which it imparts a characteristic taste and odor of natural vanilla. It is also used in perfumes, as an analytical reagent and as an intermediate in the synthesis of a number of pharmaceuticals, particularly methyl- dopa. Additionally, it has been investigated as a potential therapeutic agent in sickle cell anemia(1) and is claimed to have some antifungal properties.(2)
In food applications, vanillin has been investigated as a preservative.(3,4)
As a pharmaceutical excipient, vanillin is used in tablets, solutions (0.01–0.02% w/v), syrups, and powders to mask the unpleasant taste and odor characteristics of certain formula- tions, such as caffeine tablets and polythiazide tablets. It is similarly used in film coatings to mask the taste and odor of vitamin tablets.
�
Typical Properties
Acidity/alkalinity: aqueous solutions are acid to litmus. Boiling point: 284–2858C (with decomposition) Density (bulk): 0.6 g/cm3
Flash point: 1538C (closed cup) Melting point: 81–838C Solubility: see Table II.
Specific gravity: 1.056 (liquid)
Table II: Solubility of vanillin.
Solvent Solubility at 208C
unless otherwise stated
Acetone Soluble
Alkali hydroxide solutions Soluble
Chloroform Soluble
Ethanol (95%) 1 in 2
Ethanol (70%) 1 in 3
Ether Soluble
Glycerin 1 in 20
Methanol Soluble
Oils Soluble
Water 1 in 100
1 in 16 at 808C
Vanillin 799
Stability and Storage Conditions
Vanillin oxidizes slowly in moist air and is affected by light.
Solutions of vanillin in ethanol decompose rapidly in light to give a yellow-colored, slightly bitter tasting solution of 6,6'- dihydroxy-5,5'-dimethoxy-1,1'-biphenyl-3,3'-dicarbaldehyde. Alkaline solutions also decompose rapidly to give a brown- colored solution. However, solutions stable for several months may be produced by adding sodium metabisulfite 0.2% w/v as an antioxidant.(6)
The bulk material should be stored in a well-closed container, protected from light, in a cool, dry place.
Incompatibilities
Incompatible with acetone, forming a brightly colored com- pound.(7) A compound practically insoluble in ethanol is formed with glycerin.
Method of Manufacture
Vanillin occurs naturally in many essential oils and particularly in the pods of Vanilla planifolia and Vanilla tahitensis. Industrially, vanillin is prepared from lignin, which is obtained from the sulfite wastes produced during paper manufacture. Lignin is treated with alkali at elevated temperature and pressure, in the presence of a catalyst, to form a complex mixture of products from which vanillin is isolated. Vanillin is then purified by successive recrystallizations.
Vanillin may also be prepared synthetically by condensa- tion, in weak alkali, of a slight excess of guaiacol with glyoxylic acid at room temperature. The resultant alkaline solution, containing 4-hydroxy-3-methoxymandelic acid is oxidized in air, in the presence of a catalyst, and vanillin is obtained by acidification and simultaneous decarboxylation. Vanillin is then purified by successive recrystallizations.
Safety
There have been few reports of adverse reactions to vanillin, although it has been speculated that cross-sensitization with other structurally similar molecules, such as benzoic acid, may occur.(8) Adverse reactions that have been reported include contact dermatitis(9) and bronchospasm caused by hypersensi- tivity.(10)
The WHO has allocated an estimated acceptable daily intake for vanillin of up to 10 mg/kg body-weight.(11)
LD50 (guinea pig, IP): 1.19 g/kg(12) LD50 (guinea pig, oral): 1.4 g/kg LD50 (mouse, IP): 0.48 g/kg
LD50 (rat, IP): 1.16 g/kg LD50 (rat, oral): 1.58 g/kg LD50 (rat, SC): 1.5 g/kg
Handling Precautions
Observe normal precautions appropriate to the quantity of material handled. Eye protection is recommended. Heavy airborne concentrations of dust may present an explosion hazard.
�
Regulatory Status
GRAS listed. Included in the FDA Inactive Ingredients Guide (oral solutions, suspensions, syrups, and tablets). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.
Related Substances
Ethyl vanillin.
Comments
One part of synthetic vanillin is equivalent to 400 parts of vanilla pods. The EINECS number for vanillin is 204-465-2.
Specific References
Abraham DJ, Mehanna AS, Wireko FC, et al. Vanillin, a potential agent for the treatment of sickle cell anemia. Blood 1991; 77: 1334–1341.
Lisa´ M, Leifertova´ I, Baloun J. A contribution to the antifungal effect of propolis [in German]. Folia Pharm 1989; 13(1): 29–44.
Fitzgerald DJ, Stratford M, Narbad A. Analysis of the inhibition of food spoilage yeasts by vanillin. Int J Food Microbiol 2003; 86(1–2): 113–122.
Fitzgerald DJ, Stratford M, Gasson MJ, Narbad A. The potential application of vanillin in preventing yeast spoilage of soft drinks and fruit juices. J Food Prot 2004; 67(2): 391–395.
Thoma K, Klimek R. Photostabilization of drugs in dosage forms without protection from packaging materials. Int J Pharm 1991; 67: 169–175.
Jethwa SA, Stanford JB, Sugden JK. Light stability of vanillin solutions in ethanol. Drug Dev Ind Pharm 1979; 5: 79–85.
Thakur AB, Dayal S. Schiff base formation with nitrogen of a sulfonamido group. J Pharm Sci 1982; 71: 1422.
Weiner M, Bernstein IL. Adverse Reactions to Drug Formulation Agents: A Handbook of Excipients. New York: Marcel Dekker, 1989: 238–239.
Wang X-S, Xue Y-S, Jiang Y, et al. Occupational contact dermatitis in manufacture of vanillin. Chin Med J 1987; 100: 250–254.
Van Assendelft AHW. Bronchospasm induced by vanillin and lactose. Eur J Respir Dis 1984; 65: 468–472.
FAO/WHO. Specifications for the identity and purity of food additives and their toxicological evaluation: some flavouring substances and non-nutritive sweetening agents. Eleventh report of the joint FAO/WHO expert committee on food additives. World Health Organ Tech Rep Ser 1968; No. 383.
Lewis RJ, ed. Sax’s Dangerous Properties of Industrial Materials,
11th edn. New York: Wiley, 2004: 3661–3662.
General References
Clark GS. Vanillin. Perfum Flavor 1990; 15(Mar/Apr): 45–54. Rhodia Inc. Technical literature: Rhovanil. 2001.
Rees DI. Determination of vanillin and ehtyl vanillin in food products.
Chem Ind 1965; 1: 16–17.
Authors
PJ Weller.
Date of Revision
18 August 2005.
Vegetable Oil, Hydrogenated
Nonproprietary Names
BP: Hydrogenated vegetable oil JP: Hydrogenated oil
USPNF: Hydrogenated vegetable oil
See also Sections 8,9, and 17.
Synonyms
Some trade names for materials derived from stated vegetable oils are shown below:
Hydrogenated cottonseed oil: Akofine; Lubritab; Sterotex. Hydrogenated palm oil: Softisan 154.
Hydrogenated soybean oil: Lipovol HS-K; Sterotex HM.
Chemical Name and CAS Registry Number
Hydrogenated vegetable oil [68334-00-9] Hydrogenated soybean oil [8016-70-4]
Empirical Formula and Molecular Weight
The USPNF 23 defines two types of hydrogenated vegetable oil, type I and type II, which differ in their physical properties and applications; see Sections 9 and 17.
�Description
Hydrogenated vegetable oil is a mixture of triglycerides of fatty acids. The two types that are defined in the USPNF 23 are characterized by their physical properties; see Section 9.
Hydrogenated vegetable oil type I occurs in various forms,
e.g. fine powder, flakes, or pellets. The color of the material depends on the manufacturing process and the form. In general, the material is white to yellowish-white with the powder grades appearing more white-colored than the coarser grades.
Pharmacopeial Specifications
See Table I.
Table I: Pharmacopeial specifications for hydrogenated vegetable oil.
Test BP 2004 JP 2001 USPNF 23
Type I Type II
Identification + — — — Characters + + — — Melting range 57–708C — 57–858C 20–508C
Heavy metals 410 ppm + 40.001% 40.001%
Structural Formula
R1COOCH —CH(OOCR2)—CH OOCR3
�Moisture and
coloration
�— + — —
2 2
where R1, R2, and R3 are mainly C15 and C17.
Functional Category
Tablet and capsule lubricant; tablet binder.
Applications in Pharmaceutical Formulation or Technology
Hydrogenated vegetable oil type I is used as a lubricant in tablet and capsule formulations.(1,2) It is used at concentrations of 1–6% w/w, usually in combination with talc. It may also be used as an auxiliary binder in tablet formulations.
Hydrogenated vegetable oil type I is additionally used as the matrix-forming material in lipophilic-based controlled-release formulations;(3–6) it may also be used as a coating aid in controlled-release formulations.
Other uses of hydrogenated vegetable oil type I include use as a viscosity modifier in the preparation of oil-based liquid and semisolid formulations; in the preparation of suppositories, to reduce the sedimentation of suspended components and to improve the solidification process; and in the formulation of liquid and semisolid fills for hard gelatin capsules.(7)
Fully hydrogenated vegetable oil products may also be used as alternatives to hard waxes in cosmetics and topical pharmaceutical formulations.
See also Section 17.
�
impurities
Typical Properties
Density (tapped): 0.57 g/cm3 for Lubritab
Melting point: 61–668C for Lubritab
Particle size distribution: 85% < 177 mm, 25% < 74 mm in size for Lubritab. Average particle size is 104 mm.
Solubility: soluble in chloroform, petroleum spirit, and hot propan-2-ol; practically insoluble in water.
Stability and Storage Conditions
Hydrogenated vegetable oil type I is a stable material; typically it is assigned a 2-year shelf-life.
The bulk material should be stored in a well-closed container in a cool, dry place.
Vegetable Oil, Hydrogenated 801
Incompatibilities
Incompatible with strong oxidizing agents.
Method of Manufacture
Hydrogenated vegetable oil type I is prepared from refined vegetable oils, which are hydrogenated using a catalyst.
Safety
Hydrogenated vegetable oil type I is used in food products and oral pharmaceutical formulations and is generally regarded as a nontoxic and nonirritant excipient.
Handling Precautions
Observe normal precautions appropriate to the circumstances and quantity of material handled. Gloves, eye protection, and a dust mask are recommended when handling fine powder grades.
Regulatory Status
GRAS listed. Included in the FDA Inactive Ingredients Guide (oral capsules and tablets; rectal and vaginal suppositories and topical preparations). Included in nonparenteral medicines licensed in the UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients.
Related Substances
Castor oil, hydrogenated; hydrogenated vegetable oil, type II; medium-chain triglycerides; suppository bases.
Hydrogenated vegetable oil, type II
Comments: hydrogenated vegetable oil type II includes partially hydrogenated vegetable oils from different sources that have a wide range of applications. In general, type II materials have lower melting ranges and higher iodine values than type I materials. Many type II materials are prepared to meet specific customer requirements for use in cosmetics. Type II materials may also be used in the manufacture of suppositories. See also Section 9.
Comments
Products from different manufacturers may vary owing to differences in the source of the vegetable oil used for
�
hydrogenation. Certain materials are made from mixed hydrogenated oils, e.g. hydrogenated soybean oil and hydro- genated castor oil (Sterotex K).
Specific References
Ho¨ lzer AW, Sjo¨ gren J. Evaluation of some lubricants by the comparison of friction coefficients and tablet properties. Acta Pharm Suec 1981; 18: 139–148.
Staniforth JN. Use of hydrogenated vegetable oil as a tablet lubricant. Drug Dev Ind Pharm 1987; 13: 1141–1158.
Lockwood PJ, Baichwal AR, Staniforth JN. Influence of drug type and formulation variables on mechanisms of release from wax matrices. Proc Int Symp Control Release Bioact Mater 1987; 14: 198–199.
Wang PY. Lipids as excipients in sustained release insulin implants.
Int J Pharm 1989; 54: 223–230.
C¸ iftc¸i K, C¸ apan Y, O¨ ztu¨ rk O, Hincal AA. Formulation and in
vitro–in vivo evaluation of sustained release lithium carbonate tablets. Pharm Res 1990; 7: 359–363.
Watanbe Y, Kogoshi T, Amagai Y, Matsumoto M. Preparation and evaluation of enteric granules of aspirin prepared by acylglycerols. Int J Pharm 1990; 64: 147–154.
Du¨ rr M, Fribolin HU, Gneuss KD. Dosing of liquids into liquid gelatin capsules at the production scale: development of composi- tions and procedures [in German]. Acta Pharm Technol 1983; 29(3): 245–251.
General References
Banker GS, Peck GE, Baley G. Tablet formulation and design. In: Lieberman HA, Lachman L, eds. Pharmaceutical Dosage Forms: Tablets I. New York: Marcel Dekker, 1989.
Bardon J, Se´bert P, Chaumat C, et al. Temperature elevation undergone by mixtures of powders or granules during their transformation into tablets II: influence of nature and rate of lubricant [in French]. STP Pharma 1985; 1: 948–955.
Miller TA, York P. Pharmaceutical tablet lubrication. Int J Pharm 1988;
41: 1–19.
Staniforth JN, Cryer S, Ahmed HA, Davies SP. Aspects of pharmaceu- tical tribology. Drug Dev Ind Pharm 1989; 15: 2265–2294.
Authors
RC Moreton.
Date of Revision
26 August 2005.
Water
Nonproprietary Names
BP: Purified water JP: Purified water
�Table I: Typical applications of specific grades of water.
Type Use
PhEur: Aqua purificata USP: Purified water
�Bacteriostatic water for injection
�Diluent for ophthalmic and multiple-dose injections.
See also Sections 8 and 17.
No comments:
Post a Comment
اكتب تعليق حول الموضوع